An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)

Inclusion Criteria

• •Type 2 diabetes participants
• •De novo treatment (first prescription or dated within the past 8 weeks) with:
• •Metformin + sitagliptin dual therapy,
• •Metformin + sulfonylurea dual therapy,
• •Sitagliptin as part of another treatment regimen
• •Participants also eligible for treatment with sitagliptin (Januvia®/Xelevia®) or a sulfonylurea.